Bayer Recalls Leukine Sargramostim Vials Due to Impurities
Bayer HealthCare Pharmaceuticals is recalling Leukine sargramostim vials because a confirmed out-of-specification result for impurities was found in one lot.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this as a Class III recall, which the rubric defines as typically resulting in a score of 1 or 2 because it is unlikely to cause adverse health consequences.
Plain-English summary
Bayer HealthCare Pharmaceuticals Inc. is recalling 138,505 vials of Leukine sargramostim 5 x 500 mcg/mL liquid injection. The recall is due to a confirmed out-of-specification result for impurities or degradation products in lot B18827, which was detected at the three-month time point.
The affected product is distributed nationwide. The recall includes vials with the following lot numbers and expiration dates: B18511 (Exp. 04/12), B18513 (Exp. 05/12), B18515 (Exp. 06/12), B18517 (Exp. 06/12), B18825 (Exp. 10/12), and B18831 (Exp. 12/12). The source text does not specify if other lots are affected, but the recall quantity covers the specified distribution.
Consumers and healthcare providers should stop using the affected product and contact their healthcare provider or the recalling firm for instructions on disposal or replacement. The FDA has classified this as a Class III recall, indicating that the violation is not likely to cause adverse health consequences.
The recalled product
- Product
- Leukine sargramostim 5 x 500 mcg/mL vial, liquid injection, Sterile Rx only, Mfd by: Bayer HealthCare Pharmaceuticals, LLC Seattle, WA 98101 U.S. Lic. No. 1791 NDC 58468-0181-2
- Manufacturer
- Bayer HealthCare Pharmaceuticals Inc.
- Category
- Drug — Injectable Medication
- Affected units
- 138,505
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- B18511 Exp. 04/12
- B18513 Exp. 05/12
- B18515 Exp. 06/12
- B18517 Exp. 06/12
- B18825 Exp. 10/12
- B18831 Exp.12/12
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Bayer HealthCare Pharmaceuticals Inc.
See all →- SeverePrescription drug oral solution recalled for microbial contamination
FDA (Drugs) · 2023-12-06
- SevereLOTRIMIN AF Powder Spray Recalled for Benzene Contamination Risk
FDA (Drugs) · 2021-11-24
- SevereLotrimin AF Powder Spray Recalled for Benzene Contamination
FDA (Drugs) · 2021-11-24
- HighLotrimin Daily Prevention Deo Spray Recalled for Benzene Contamination Risk
FDA (Drugs) · 2021-11-24
- HighLotrimin Daily Prevention Deo recalled for potential benzene contamination
FDA (Drugs) · 2021-11-24
Same hazard · impurities
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateGlycopyrrolate Oral Solution Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-29
- ModerateMethohexital Sodium for Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-15
- ModerateMethohexital Sodium 100 mg/10 mL Compounded Drug Recalled Nationwide
FDA (Drugs) · 2026-07-15
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08